Ottensmeier CHH, Delord JP, Lalanne A, Lantz O, Jamet C, Tavernaro A, et al. Safety and immunogenicity of TG4050: a personalized cancer vaccine in head and neck carcinoma. J Clin Oncol. 2023;41:6082.

Article  Google Scholar 

Aggarwal C, Ben-Shachar R, Gao Y, Hyun SW, Rivers Z, Epstein C, et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw Open. 2023;6:e2311181.

Article  PubMed  PubMed Central  Google Scholar 

Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol. 2023;7:e2300092.

Article  PubMed  PubMed Central  Google Scholar 

Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21:261–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632–44.

Article  CAS  PubMed  Google Scholar 

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021;18:955–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Seclì L, et al. Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine. Cancer Immunol Res. 2024;12:440–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399:1313–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification. Clin Cancer Res. 2021;27:689–703.

Article  CAS  PubMed  Google Scholar 

Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8:450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7.

Article  PubMed  PubMed Central  Google Scholar 

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37.

Article  PubMed  PubMed Central  Google Scholar 

Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.

Article  PubMed  PubMed Central  Google Scholar 

Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009;15:2130–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue W, Metheringham RL, Brentville VA, Gunn B, Symonds P, Yagita H, et al. SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology. 2016;5:e1169353.

Article  PubMed  PubMed Central  Google Scholar 

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7:38.

Article  PubMed  PubMed Central  Google Scholar 

Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107–12.

Article  CAS  PubMed  Google Scholar 

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.

Article  PubMed  Google Scholar 

Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 2018;592:2023–31.

Article  CAS  PubMed  Google Scholar 

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829–40.

Article  CAS  PubMed  Google Scholar 

Jo JH, Kim YT, Choi HS, Kim HG, Lee HS, Choi YW, et al. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial. Br J Cancer. 2024;130:43–52.

Article  CAS  PubMed  Google Scholar 

Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, et al. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. J Immunother Cancer. 2021;9:e003019.

Article  PubMed  PubMed Central  Google Scholar 

Reardon DA, Brem S, Desai AS, Bagley SJ, Kurz SC, De La Fuente MI, et al. Intramuscular (IM) INO-5401+INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. J Clin Oncol. 2022. https://doi.org/10.1200/JCO.2022.40.16_suppl.2004.

Article  PubMed  PubMed Central  Google Scholar 

Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, et al. A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors. Clin Cancer Res. 2020;26:588–97.

Article  CAS  PubMed  Google Scholar 

Kang J, Park H-H, Choi JH, Lim J, Jang S-Y, Kim M-A, et al. 897 AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model. J Immunother Cancer. 2023;11:A999.

Google Scholar 

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, et al. Vaccine-induced memory CD8(+) T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clin Cancer Res. 2019;25:2725–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Linch M, Papai Z, Takacs I, Imedio ER, Kühnle M-C, Derhovanessian E, et al. 421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT. J Immunother Cancer. 2021;9:A451.

Google Scholar 

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001–11.

Article  CAS  PubMed  PubMed Central